Jennifer Evans Stacey - 24 Jun 2026 Form 4 Insider Report for Context Therapeutics Inc. (CNTX)

Reporting relationship: Director
Issuer ticker: CNTX
Reported as of: 24 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Jun 2026, 16:21:41 UTC
Prior SEC filing: 04 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Alex Levit, Attorney-in-Fact

Key filing fact

Jennifer Evans Stacey filed Form 4 for Context Therapeutics Inc. (CNTX) on 26 Jun 2026.

Key facts

This page summarizes Jennifer Evans Stacey's Form 4 filing for Context Therapeutics Inc. (CNTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 26 Jun 2026, 16:21.

Change

Previous filing in this sequence was filed on 04 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001321326 Primary reporting owner

Stacey Jennifer Evans

Relationship: Director
Address: 2001 MARKET STREET, SUITE 3915, UNIT #15, PHILADELPHIA
Signature: /s/ Alex Levit, Attorney-in-Fact
Signature date: 26 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CNTX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +45,000
Change %
Price: $0.000000^*
Shares after: 45,000
Date: 24 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 45,000
Exercise price: $0.5760
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests and becomes exercisable on the earlier of (i) June 24, 2027 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2027 annual meeting of stockholders, subject to continued service with the Issuer.